ScottW.DahlbeckMD

Radiation Oncology • Houston, TX

Urologic Cancer

UMC Southwest Cancer Center

Join to view full profile

Dr. Dahlbeck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dahlbeck's full profile

Already have an account?

Office
7707 Fannin St Ste 200
Houston, TX 77054
Phone+1 713-689-4450

Fax+1 806-775-8608

Education & Training

Kaiser Permanente Southern California (Los Angeles)Residency, Radiation Oncology, 1999 - 2003
Hennepin HealthcareResidency, Family Medicine, 1993 - 1995
University of MinnesotaResidency, Radiation Oncology, 1993 - 1993
Methodist Hospital (Houston)Internship, Family Medicine, 1992 - 1993
McGovern Medical School at UTHealthClass of 1992

Certifications & Licensure

CA State Medical License 1999 - 2026
TX State Medical License 1986 - 2026
NM State Medical License 2003 - 2006
MN State Medical License 1994 - 1999
American Board of Radiology Radiation Oncology

Publications & Presentations

PubMed

66 citations
Galectins in cancer: carcinogenesis, diagnosis and therapy
Ali Hasan Ebrahim, Zainab Alalawi, Leonardo Mirandola, Rahman Rakhshanda, Scott Dahlbeck
Annals of Translational Medicine. 2014-09-28
12 citations
PSA screening and deaths from prostate cancer after diagnosis—a population based analysis
Mitchell S. Wachtel, Thomas Nelius, Allan Haynes, Scott Dahlbeck, Werner de Riese
The Prostate. 2013-09-01
3 citations
The role of radiation therapy in children with acute lymphoblastic leukemia kidney infiltration.
Scott W. Dahlbeck, Michael Tome, A. Robert Kagan, Robert Cooper
Medical and Pediatric Oncology. 2001-11-01

Press Mentions

Kiromic Announces Expansion of in-House Cell Therapy cGMP Manufacturing Facility and the Appointment of Industry Veteran Ignacio Núñez as Chief Operating and Manufacturing OfficerJune 7th, 2021
Kiromic Announces FDA IND Submission First-in-Human, AI Derived Off-the-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy, 30 Days Before the End of the Second QuarterMay 24th, 2021
Kiromic to Resubmit Two Expanded INDs to the FDA for Its Allogenic, Off-the-Shelf Gamma-Delta T Cell Therapies for Multiple Solid TumorsMarch 9th, 2021
Join now to see all